We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




TB Tests Assessed to Diagnose Pregnant HIV Positive Women

By LabMedica International staff writers
Posted on 09 Feb 2016
Print article
The QuantiFERON Gold interferon gamma release assay for tuberculosis
The QuantiFERON Gold interferon gamma release assay for tuberculosis (Photo courtesy of QUEST DIAGNOSTICS)
The most commonly used test for tuberculosis (TB) fails to accurately diagnose the disease in up to 50% percent of pregnant women who are positive for the human immunodeficiency virus (HIV+).

The performance of latent TB infection (LTBI) tests has been assessed in HIV-infected pregnant and postpartum women, and the immunology behind discordance in pregnancy investigated, and the implications for the development of postpartum tuberculosis explored.

Scientists at the Weill Cornell Medical College (New York, NY, USA) and their colleagues form other institutions enrolled 252 women who were in their second or third trimester and receiving care at a public teaching hospital in India. The women received TB testing at enrollment during pregnancy or at delivery. An additional 39 women participated in a longitudinal study to assess how the TB tests were affected by changes in different stages of pregnancy. They were tested at delivery and three months postpartum. The investigators also collected blood samples to assess for levels of infection-fighting proteins.

The teams screened pregnant women in their 2nd/3rd trimester and at delivery for LTBI using the tuberculin skin test (TST) and QuantiFERON Gold interferon gamma release assay (IGRA), (Quest Diagnostics; Madison, NJ, USA). A subset of antepartum women had longitudinal testing, with repeat testing at delivery and postpartum and additional cytokines measured from the IGRA supernatant. Of 252 enrolled, 71 (28%) women had a positive IGRA, but only 27 (10%) had a positive TST, and there was 75% agreement. When stratified by pregnancy versus delivery, 20% had IGRA+/TST- discordance at each time point. A positive IGRA was associated with known TB contact. Compared to IGRA+/TST+, women with IGRA+/TST- discordance produced significantly less interferon gamma (IFN-γ; 1.85 IU/mL vs 3.48 IU/mL, and less interleukin 2 (IL-2; 46.17 pg/mL vs. 84.03 pg/mL). Five developed postpartum tuberculosis, of which three had IGRA+/TST- discordance during pregnancy.

Jyoti Mathad, MD, MSc, the lead author of study said, “We found that QuantiFERON Gold positivity was almost three times higher than the more widely used TST at every time point tested. Our blood data suggests that pregnant women produce lower levels of the immune chemicals that many TB diagnostics test for. This finding has implications beyond diagnostics. For example, not all pregnant women lose immune control of TB infection. But, currently we have no way of predicting which women are most likely to get sick from the disease. Our findings about these immune chemicals provide a starting point for developing a test that will tell us who in this already high-risk population is at greatest risk of disease and death and is in most need of treatment.” The study was published on January 14, 2016, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:

Weill Cornell Medical College 
Quest Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.